

1 **Genomic insights into the mechanism of NK3R antagonists for treatment of menopausal**
2 **vasomotor symptoms**

3 Katherine S. Ruth¹, Robin N. Beaumont¹, Jonathan M. Locke¹, Jessica Tyrrell¹, Carolyn J. Crandall²,
4 Gareth Hawkes¹, Timothy M. Frayling¹, Julia K. Prague^{3,4}, Kashyap A. Patel^{3,4}, Andrew R. Wood¹,
5 Michael N. Weedon¹, Anna Murray^{1*}

6 ¹Genetics of Complex Traits, University of Exeter Medical School, University of Exeter, Exeter, EX2
7 5DW, UK.

8 ²Division of General Internal Medicine and Health Services Research, David Geffen School of
9 Medicine at University of California, Los Angeles, CA 90024, USA.

10 ³Exeter Centre of Excellence for Diabetes Research, University of Exeter, Exeter, EX2 5DW, UK.

11 ⁴Macleod Diabetes and Endocrinology Centre, Royal Devon and Exeter National Health Service
12 Foundation Trust, Exeter, EX2 5DW, UK.

13 *Correspondence to Anna Murray (a.murray@exeter.ac.uk)

14 **Research in context**

15 *Evidence before the study*

16 *In vivo* studies of animal models and clinical studies in humans have determined that menopausal
17 vasomotor symptoms (VMS) result from increased neurokinin B (NKB) signalling via the neurokinin 3
18 receptor (NK3R) in response to decreased circulating oestradiol levels.

19 Recent Phase II clinical trials have demonstrated the efficacy of NK3R antagonists in reducing VMS.

20 A previous GWAS in 17,695 women identified a genetic signal at the *TACR3* locus (which codes for
21 NK3R) as associated with VMS. The locus was also genome-wide significant in a GWAS of
22 oestrogen-replacement use (15,305 cases) derived from self-reported medications in UK Biobank.

23 *Added value of this study*

24 This study represents a novel approach to analysing the rarely captured phenotype of VMS, since few
25 population-based cohorts have asked about menopausal symptoms.

26 To the best of our knowledge, this is the first analyses of VMS identified from linked primary care
27 health records. Literature searches of published papers and codelists have not identified any previous
28 studies of VMS in primary care data. The replication of the known GWAS signal for VMS provides a
29 validation of the coding of this phenotype from primary care data.

30 This is the largest genomic study of VMS currently carried out (92,028 women). Our current analyses
31 are limited by the availability of primary care linked data in ~45% of the UK Biobank cohort and are
32 based on exome sequencing in 200,000 women. Recently released exome data for the full cohort and
33 further releases of primary care linked data in UK Biobank will allow us to re-visit these analyses
34 further.

35 *Implications of all the available evidence*

36 Our analyses of rare coding variation in *TACR3* identified an intriguing difference that requires further
37 study; while NK3R antagonist drug treatment reduces VMS, women carrying rare genetic variants
38 resulting in reduced NK3R levels were no less likely to experience VMS.

39 Our genome-wide analyses replicate the genetic signals for VMS at the *TACR3* gene locus, however
40 we were unable to unequivocally identify *TACR3* as the causal gene at this locus.

41 We suggest that the effect of the common genetic variant on reducing VMS may be through as yet
42 uncharacterised regulatory pathways, and that complete inhibition of NK3R signalling is required to
43 eliminate (rather than reduce) VMS.

44 **Abstract**

45 *Background*

46 Menopausal vasomotor symptoms (VMS) significantly impact women's quality of life, and whilst
47 hormone replacement therapy (HRT) is effective, it is not appropriate for all. We aimed to identify new
48 drug targets for VMS and understand reasons for HRT use through genomic analyses.

49 *Methods*

50 In up to 153,152 women from UK Biobank, a population-based cohort, we performed a genome-wide
51 association study (GWAS) of VMS derived from linked primary-care records and cross-sectional self-
52 reported data. In a subset of this cohort (n=39,356), we analysed exome-sequencing data to test the
53 association of rare deleterious genetic variants with VMS. Finally, we used Mendelian randomisation
54 analysis to investigate the reasons for HRT use and whether these changed over time.

55 *Findings*

56 Our GWAS identified a genetic signal near the gene encoding NK3R (*TACR3*) associated with a lower
57 risk of VMS (OR=0.85 (95% CI 0.82,0.87) per AT allele, $P=1.1 \times 10^{-26}$), which was consistent with
58 previous studies. However, rare genetic variants predicted to reduce functional NK3R levels were not
59 associated with VMS ($P=0.9$), though did delay puberty ($P=9 \times 10^{-11}$). Younger menopause age was
60 causally-associated with greater HRT use before 2002 but not after.

61 *Interpretation*

62 Using genomics we demonstrate that changed HRT use since the early 2000s reflects a switch from
63 preventing post-menopausal complications to primarily treating VMS. We provide support for *TACR3*
64 in the genetic basis of VMS but unexpectedly find that rare genomic variants predicted to lower NK3R
65 levels did not modify VMS, despite the proven efficacy of NK3R antagonists, suggesting that further
66 biological understanding could benefit therapeutic efficacy.

67 *Funding*

68 Cancer Research UK and UKRI.

69 Introduction

70 Vasomotor symptoms (VMS) in postmenopausal women include hot flashes and night sweats, which
71 can have debilitating and long-lasting effects on quality of life, with 10% of women experiencing VMS
72 for up to 12 years.¹ Hormone replacement therapy (HRT) is the most effective treatment for VMS
73 around menopause but its popularity amongst the public and health professionals declined following
74 the publication of adverse outcome data² and it is contraindicated in some women, such as those who
75 have had breast cancer. Consequently, there is great interest in identifying non-oestrogen drug
76 treatments for VMS.

77 VMS result from dysfunction of thermoregulation by the hypothalamus and autonomic
78 thermoregulatory system caused by increased neurokinin B (NKB) /neurokinin 3 receptor (NK3R; also
79 known as the neuromedin-K receptor or tachykinin receptor 3) signalling in response to decreased
80 circulating oestradiol levels, as shown *in vivo* in animal models.^{3,4} Four Phase 2 clinical trials have
81 demonstrated that administration of a NK3R receptor antagonist results in a clinically significant
82 reduction in hot flushes comparable to that achieved by HRT.^{5–8} Such NK3R receptor antagonists are
83 currently in Phase 3 clinical trials and have not yet come to market.⁹ Neurokinin signalling also plays
84 an important role in controlling the onset of puberty¹⁰, with genetic variants that knock out the *TACR3*
85 gene (which encodes NK3R) resulting in pubertal failure in homozygous carriers^{11,12} and delayed
86 puberty in heterozygous carriers.¹³ Additionally, population-based genome-wide association studies
87 (GWAS) have identified several more common genetic variants in or near the *TACR3* gene
88 associated with normal variation in age at menarche.¹⁴

89 We aimed to increase understanding of the mechanism of VMS and to identify other novel treatment
90 targets using a combination of GWAS and exome sequencing. A previous GWAS in 17,695 women
91 identified a signal in *TACR3*.¹⁵ Our study in UK Biobank (N=153,152) included nearly 10 times more
92 women than this initial GWAS and we have used a combination of linked primary care health records
93 and self-reported questionnaire data to capture VMS by different methods to validate our findings.^{16,17}

94 Methods

95 *Phenotype definitions*

96 Between 2006–2010, UK Biobank recruited over 500,000 individuals aged 37–73 years from across
97 the UK who answered detailed questions about themselves, had measurements taken and provided
98 blood, urine and saliva sample samples, and for whom linked health records data are available.¹⁷ We
99 identified women with VMS for inclusion in our primary analyses from linked primary care records,
100 which are available for ~45% of the cohort and capture participants' contact with health care
101 professionals working at UK general practices (family physicians) over their lifetime to ~2017. Cases
102 (n=14,261) were women with one or more clinical events in the linked primary care records (e.g.
103 symptoms, history or diagnosis) containing any of 33 relevant codes for menopausal VMS
104 (Supplementary Methods; Supplementary Table 1). Controls (n=77,767) were women who were
105 included in the linked primary care records (identified through having a primary care registration

106 record without a relevant VMS code), and aged 50 and over at the baseline UK Biobank assessment
107 and so were likely to be experiencing the menopause transition and thus at risk of VMS.

108 For secondary analyses we derived proxy phenotypes for VMS based on self-reported HRT use
109 (Supplementary Methods, Supplementary Table 2). To explore the effect of the publication of adverse
110 health outcomes relating to HRT, we further subdivided the ever taking HRT group into those who
111 took HRT before and after 2002 to reflect the year of publication of the initial findings of the Women's
112 Health Initiative HRT trial¹⁸ and estimated the proportion of women taking HRT before and after 2002
113 (Supplementary Methods).

114 *Genome-wide association study analyses*

115 Genotyping of the UK Biobank study was performed centrally¹⁶. Two genotyping arrays with over 95%
116 common marker content were used to genotype the individuals; the Affymetrix Axiom UK Biobank
117 array (~450,000 individuals) and the UKBiLEVE array (~50,000 individuals). This dataset underwent
118 extensive central quality control and genotype imputation using 1000 Genomes Phase 3/UK10K and
119 Haplotype Reference Consortium reference panels. We based our study on 451,099 individuals who
120 we identified as being of European descent, as described previously.¹⁹

121 We carried out genome-wide analyses using BOLT-LMM v2.3²⁰, which uses a mixed linear model to
122 account for relatedness and ethnicity. We tested 17 million genetic variants with minor allele
123 frequency (MAF) >0.1% and imputation quality >0.3. Association testing was based on an additive
124 model and was adjusted for genotyping chip and release of the data, recruitment centre and age
125 (Supplementary Methods). Quantitative traits were inverse-rank normalised, to ensure that residuals
126 were normally distributed. Genome-wide significant variants had $P < 5 \times 10^{-8}$. For case-control traits we
127 transformed effect sizes (β) on the quantitative scale to odds ratios (using the transformation
128 $\ln(\text{OR}) = \beta / (\mu \times (1 - \mu))$, where μ is the fraction of cases) and confirmed associations using a Fisher's
129 exact test (Supplementary Methods). We performed case-control matched analyses of HRT use to
130 account for different age distributions (Supplementary Methods). Independent signals were more than
131 500kb from the next most significant variant for the same phenotype and in linkage disequilibrium
132 (LD) $r^2 < 0.5$ with signals for other VMS phenotypes. Additionally, to identify further independent signals
133 at the *TACR3* locus, we carried out conditional analysis by re-running the VMS GWAS including the
134 genotype at the lead variant as a covariate.

135 We meta-analysed the results of the VMS GWAS with summary statistics from the European cohorts
136 (GARNET and WHIMS) of Crandall et al 2017 (2,747 cases and 5,440 controls).¹⁵ Inverse-variance
137 weighted meta-analyses were carried out in METAL²¹ with genomic-control correction applied and we
138 included variants with MAF >0.1% and imputation quality >0.3.

139 *Annotation of GWAS signals*

140 We tested whether our GWAS signals were associated with age at menarche and age at menopause
141 in UK Biobank by conducting GWAS (method as described) using phenotypes consistent with those

142 used in ReproGen consortium analyses (n=106,048 for age at menopause; n=236,807 for age at
143 menarche).^{14,22} We also calculated LD between our GWAS signals and previously published signals
144 for menarche and menopause timing.^{14,22} LD was calculated for the regions around the HRT signals
145 from best guess genotypes for 1000 Genomes Phase 3/HRC imputed variants in ~340,000 unrelated
146 UK Biobank participants of white British ancestry using PLINK v1.9.²³ To identify variants with
147 functional or regulatory consequences, we looked up variants in LD with our lead genetic variant in
148 Variant Effect Predictor (build 38)²⁴, Ensembl (Human (GRCh38.p13 release 100))²⁵, HaploReg v4.1²⁶
149 and goDMC (<http://mqtldb.godmc.org.uk/>). We investigated eQTLs in $r^2 > 0.8$ with the top hits in
150 PsychENCODE²⁷ and GTEx v8 (<https://www.gtexportal.org/home>). We calculated the distance of
151 variants in $r^2 > 0.8$ with the lead genetic variant to canonical and alternative splice sites for *TACR3*
152 using Intropolis.²⁸ Manhattan and quantile–quantile plots were produced in R using the package
153 “qqman”.²⁹ LocusZoom v1.4³⁰ was used to plot the association statistics at individual loci.

154 *Exome-wide analyses*

155 We carried out analyses of association of VMS and age at menarche with rare variants using exome
156 sequencing data available in ~200,000 people from UK Biobank (Supplementary Methods).³¹ Variants
157 in CCDS transcripts were annotated using Variant Effect Predictor²⁴ and we identified loss-of-function
158 (LOF) variants (stop-gain, frameshift, or abolishing a canonical splice site (-2 or +2 bp from exon,
159 excluding the ones in the last exon)) deemed to be high confidence by LOFTEE
160 (<https://github.com/konradjk/loftee>). We conducted gene-burden analyses using SAIGE-GENE³² for
161 age at menarche and REGENIE³³ for VMS, which account for relatedness and ethnicity and are
162 suitable for analyses with unbalanced case:control ratios. We included recruitment centre and age at
163 baseline as covariates and tested the association of variants with $MAF < 0.001$ in each gene in
164 aggregate as well as individually. For each gene, we present results for the transcript with the
165 smallest burden p-value.

166 *Tests of associations of variants in the TACR3 region*

167 We investigated whether puberty timing genetic variants in/near the *TACR3* gene were also
168 associated with VMS. These variants included a rare protein truncating variant which in homozygous
169 state leads to hypogonadotropic hypogonadism and in heterozygous state to delayed menarche
170 (rs144292455 C>T p.W275X, chr4:104577415, $MAF = 0.06\%$)^{13,34} and five genetic variants associated
171 with age at menarche in GWASs (rs55784701 (chr4:104247262), rs3733632 (chr4:104640935),
172 rs62342064 (chr4:104665972), rs115260227 (chr4:104774698), rs17035311 (chr4:106066293),
173 smallest $MAF = 1.3\%$) within ~1.5Mb of *TACR3*.¹⁴ Genotypes were extracted from imputed data except
174 for rs144292455, which is a rare variant and thus poorly imputed; for this variant we used directly
175 genotyped data, which have previously been shown to be reliable.³⁵ We tested the associations of
176 these variants individually, in combination and when adjusted for genotype of our lead VMS genetic
177 variant using regression analyses. We performed logistic (binary traits) and linear (quantitative traits)
178 regression in Stata v14.0/v16.0 in 379,768 unrelated individuals of European descent.³⁶ We

179 regressed outcomes on genotype including the covariates genotyping chip and release of genotype
180 data, recruitment centre, age and the first five genetic principal components (generated as described
181 previously³⁶).

182 *Mendelian randomisation analyses*

183 Given the overlap in the genetic variants identified for HRT use and age at natural menopause, we
184 used Mendelian randomisation (MR) analyses to test whether earlier age at menopause was the
185 cause of women taking HRT, or just correlated with HRT use. We constructed a genetic instrument for
186 the exposure age at menopause from 56 published genetic variants discovered in a meta-analysis of
187 ~70,000 women that was independent of UK Biobank data.²² In each MR test we assessed a number
188 of widely used methods including inverse-variance weighted MR (IVW MR) and those more robust to
189 pleiotropy (weighted median MR, penalised weighted median MR and MR–Egger^{37,38}) to address the
190 assumption that alleles that influence the exposure do not influence the outcome via any pathway
191 other than through the exposure. We used IVW MR as our primary analysis method and interpreted
192 directionally-consistent results across the various methods as strengthening our causal inference.

193 *Heterogeneity in effects of genetic variants before and after 2002*

194 Following the publication of data on adverse effects of HRT in 2002, we hypothesized that the primary
195 reasons why women took HRT changed before and after this date, and that these differences may not
196 have been solely due to a change in preference of women and health professionals and would be
197 reflected in differences in genetic associations by time. To test this, we compared the direction of
198 effect of the lead variant for the 15 signals on ever using HRT before and after 2002. We compared
199 effect estimates from the GWAS of HRT use before and after 2002 by calculating a heterogeneity chi-
200 squared *P*-value using the package “metan” in Stata v14.0/v16.0. We carried out Mendelian
201 randomisation (as described) to test the association of genetically-instrumented age at menopause
202 with HRT use before and after 2002.

203 *Role of the funding source*

204 The funders of the study had no role in the design, data collection, data analysis, data interpretation
205 or writing of the report. AM, KSR, RNB, JT, GH, ARW, MNW and TMF had access to the raw data.
206 The corresponding author had full access to all the data in the study and final responsibility for the
207 decision to submit for publication.

208 **Results**

209 We identified 14,261 women with VMS and 77,767 controls from linked primary care records in UK
210 Biobank for inclusion in our genome-wide association study (GWAS) of VMS (Table 1). From our
211 GWAS we identified a single independent genetic signal (lead variant rs34867104) associated with
212 lower odds of having VMS ((OR=0.78 (95% CI 0.74,0.82) per AT allele; allele frequency (AF) = 5.5%;

213 $P=1.7 \times 10^{-20}$) (Supplementary Figure 1, Figure 1). Meta-analysis of the UK Biobank VMS GWAS with
214 that from Crandall et al 2017¹⁵ replicated the same single genetic signal in the *TACR3* gene
215 (OR=0.76 per A allele (95% CI 0.72, 0.80; $P=3.7 \times 10^{-27}$) (Table 2). No further independent signals at
216 $P < 5 \times 10^{-8}$ were identified when we performed GWAS conditioning on the genotype at the lead variant
217 (rs34867104). *In silico* analyses found little evidence to suggest a biological mechanism for the
218 GWAS signal. There were no non-synonymous variants (with effects on protein sequence) strongly
219 correlated with the signal (LD $r^2 > 0.8$), and there was little evidence for an effect on gene expression,
220 regulation or splicing (Supplementary Results). However, based on clinical studies that have
221 demonstrated that NK3R antagonists reduce VMS^{5,39,40}, *TACR3* is the most likely causal gene in this
222 region.

223 Using exome sequencing data available for 6,280 women with VMS and 33,076 controls we
224 investigated the effect of reduced levels of *TACR3* protein on VMS using genetic variants in *TACR3*
225 predicted with high confidence to result in no protein product (i.e. LOF variants). We tested the
226 association with VMS of a *TACR3* LOF allele rs144292455 C>T p.W275X (MAF=0.06%) previously
227 reported as associated with delayed menarche^{13,34} and all rare (MAF<0.1%) LOF variants in *TACR3*
228 in aggregate. There was little evidence of an association between *TACR3* LOF and VMS
229 (rs144292455 $P=0.6$, 8/41 carriers were VMS cases vs 6,272/39,315 non-carriers; aggregate LOF
230 burden $P=0.9$, 8/49 carriers were VMS cases vs 6,272/39,307 non-carriers), though *TACR3* LOF was
231 associated with delayed age at menarche (rs144292455 $P=5.0 \times 10^{-9}$, 105 carriers vs 98,386 non-
232 carriers; aggregate LOF burden $P=8.6 \times 10^{-11}$, 128 carriers vs 98,363 non-carriers) (Supplementary
233 Table 3). Associations of rs144292455 with VMS and age at menarche were consistent when we
234 repeated the analysis in a larger sample of directly genotyped chip data (18/79 carriers were VMS
235 cases vs 11,832/76,335 non-carriers) (Supplementary Table 4). We further confirmed the
236 independence of the VMS GWAS signal (rs34867104) and rs144292455 through conditional analyses
237 (Supplementary Table 4). Several GWAS signals for age at menarche are in the *TACR3* region,
238 however these have a different underlying genetic basis to the signal for VMS (Figure 1,
239 Supplementary Results and Supplementary Table 5). Therefore, our genetic analyses suggest that
240 individuals with loss of *TACR3* have later puberty but do not have fewer VMS.

241 Next we increased our sample size by employing HRT use as a proxy phenotype for VMS, identifying
242 variant rs34867104 as the most strongly associated signal for HRT use (Table 2) (OR=0.85 (95% CI
243 0.82,0.87) per AT allele, $P=1.1 \times 10^{-26}$), with consistent results in age-matched sensitivity analyses
244 (OR=0.83 (95% CI 0.80,0.86)). Our secondary analyses resulted in a further 14 independent genetic
245 signals associated with HRT phenotypes that did not reach genome-wide significance in the VMS
246 GWAS (all $P > 0.05$) (Supplementary Results, Supplementary Table 6). However, 11 of the 14 signals
247 represented associations with HRT use as a consequence of early menopause; 10 signals were
248 associated with menopause timing at $P < 5 \times 10^{-8}$ in the largest genome-wide meta-analysis of age at
249 natural menopause⁴¹, with a further signal associated ($P < 5 \times 10^{-8}$) in UK Biobank (Supplementary
250 Table 6). Furthermore, Mendelian randomisation analyses showed that menopause timing is causally
251 associated with HRT use, with a one-year genetically-instrumented earlier age at menopause strongly
252 associated with higher odds of taking HRT (OR=1.10 (1.08,1.12), $P=1 \times 10^{-18}$) (Supplementary Table

253 7). In contrast, the VMS signal at *TACR3* (rs34867104) was not associated with menopause timing
254 (Supplementary Table 6) and the genetic instrument for menopause timing showed little association
255 with VMS (IVW MR $P > 0.05$). Three additional genetic signals near *C3orf43*, *LINC01010* and *PINX1*
256 were not associated with menopause timing and represent putative VMS signals highlighted by our
257 proxy GWAS (Supplementary Table 6).

258 Following the publication of adverse effects of HRT in 2002, we hypothesized that only women with
259 severe VMS took HRT, considering the benefit to outweigh the risk, and that these differences will be
260 reflected in genetic associations. In UK Biobank we identified a change in the proportion of women
261 using HRT from 49% before 2002 to 14% after 2002. By testing the association of genetically-
262 instrumented age at menopause with HRT use before and after 2002, we found that a one-year
263 genetically-predicted earlier menopause raised the odds of HRT use before 2002 (OR=1.12, 95%
264 CI=1.10,1.13), but not after 2002 (OR=0.98, 95% CI=0.95,1.00) (Figure 2), with concordant results in
265 age-matched sensitivity analyses (Supplementary Table 7). Consistent with this finding, the signals
266 that were associated with age starting HRT as a result of menopause timing had opposite effects on
267 HRT use before and after 2002 (Supplementary Table 8). In contrast, the genetic signal in *TACR3*
268 (rs34867104) was associated with lower odds of using HRT both before and after 2002 (before 2002,
269 OR=0.85 per AT allele (95% CI 0.83,0.88), $P=1.6 \times 10^{-21}$; after 2002, OR=0.83 per AT allele (95% CI
270 0.77,0.89), $P=1.4 \times 10^{-6}$; P test of heterogeneity=0.48). Two of the putative VMS signals (rs201598433
271 near *C3orf43* and rs200480420 near *LINC01010*) also showed little evidence of heterogeneity in
272 effects pre/post 2002 (Supplementary Table 8), strengthening the evidence that they are candidate
273 VMS signals.

274 Discussion

275 In this large study of menopausal VMS, we provide further evidence to support the role of *TACR3* in
276 the genetic basis of VMS.¹⁵ We identified considerable phenotypic and genetic heterogeneity at the
277 *TACR3* locus that should be explored further to provide important insight into potential therapies
278 targeted at *TACR3*. Our analyses provide support for using HRT as a proxy phenotype for VMS,
279 suggesting the possibility for expanded future GWAS analyses as this phenotype may be more
280 available than that of VMS in genetic studies. However, we show that genetic associations with
281 therapeutic phenotypes need to be considered in the context of any major changes in the use of that
282 therapy in routine clinical practice. Based on our results we suggest that HRT use post-2002 is more
283 appropriate for capturing severe menopausal symptoms than pre-2002 use.

284 We replicated a genetic signal in *TACR3* associated with VMS¹⁵, adding to genetic evidence for a role
285 of NK3R (coded for by *TACR3*) in VMS. In postmenopausal women, oestrogen withdrawal results in
286 hypertrophy of kisspeptin-neurokinin B-dynorphin secreting (KNDy) neurons in the infundibular
287 nucleus of the hypothalamus, which increase mRNA expression of NKB, dynorphin, kisspeptin,
288 substance P and ER α .⁴² Studies in rodents have shown that increased levels of NKB result in more
289 signalling through NK3R, stimulating pre-optic thermoregulatory areas of the hypothalamus but do not
290 entirely exclude contributions of other KNDy peptides to thermoregulation (i.e. dynorphin, kisspeptin

291 and substance P).^{3,4} In humans, previous studies have demonstrated that infusion of NKB in pre-
292 menopausal women induces menopausal VMS⁴⁰ and, in clinical trials, that NK3R antagonists reduce
293 VMS in menopausal women^{5,39,40}.providing support for *TACR3* as the most likely causal gene in the
294 GWAS locus. However, our *in silico* analyses found no additional evidence to confirm *TACR3* as the
295 causal gene and we identified no reduction in VMS in 41 heterozygous carriers of a rare loss-of-
296 function genetic variant in *TACR3* (rs144292455)^{34,43} in whom NK3R expression should be reduced.
297 Thus we cannot rule out the possibility that *TACR3* is not the causal gene for the VMS GWAS signal
298 and that the GWAS signal is tagging a variant with an effect on another gene. Other published GWAS
299 studies have identified significant signals in *TACR3* associated with testosterone levels (in males, and
300 males and females combined)⁴⁴, and signals near *TAC3* (which codes for NKB) as associated with
301 age at menopause⁴¹. Further expanded genomic analyses of VMS and related phenotypes and the
302 increasing availability of additional genomic data will allow these inconsistencies to be explored.

303 We provide evidence that the mechanism through which the genetic variants in *TACR3* influence
304 VMS are distinct from effects of variants in this genomic region on puberty timing, consistent with
305 known biology supporting distinct pathways. At puberty, NKB signalling is involved in the activation of
306 Kiss1 neurons, resulting in pulsatile secretion of kisspeptin and consequently gonadotropin releasing
307 hormone and luteinising hormone¹⁰. The rare variant in *TACR3* tested in our analyses (rs144292455)
308 causes a premature stop codon (p.W275X) in the fifth transmembrane segment of the 465 amino acid
309 NK3R and is predicted to be pathogenic and cause loss of function.^{34,43} Variant rs144292455 causes
310 idiopathic hypogonadotropic hypogonadism in male homozygotes³⁴ and the rare allele shows additive
311 effects, delaying menarche by 1.25 years in female heterozygotes^{13,35}, an effect confirmed in our
312 study cohort despite the lack of association with VMS. One explanation for these apparently
313 contradictory results could be that complete inhibition of NK3R signalling⁴⁵ might be required to
314 reduce VMS, and that the heterozygous women in our analyses still had sufficient NKB/NK3R
315 signalling to cause VMS, resulting in no discernible reduction in symptoms. In contrast, we suggest
316 that puberty timing appears to be sensitive to the amount of NKB/NK3R signalling. We were unable to
317 test the effects of homozygous loss-of-function of rs144292455 on VMS, as there were no such
318 women in our study cohort. Common genetic variation associated with age at menarche at the
319 *TACR3* locus is independent of rare variant rs144292455¹³ and was also not associated with VMS.
320 We propose that changes in gene regulation and expression mediate the VMS phenotype, potentially
321 through alterations in transcription factor binding, rather than the direct effects on NK3R, and that this
322 should be explored in future studies.

323 We demonstrate an interaction between a major change in clinical practice and genetic determinants
324 for HRT use, adding to the relatively small number of robust gene-by-environment interactions in the
325 literature. Overall, women with earlier menopause were more likely to use HRT. Prior to 2002, earlier
326 age at menopause increased the odds of HRT use but this relationship did not exist after 2002. In
327 contrast, the genetic signal for VMS use in *TACR3* (rs34867104) remained associated with using HRT
328 across the time period and was not associated with menopause timing. We suggest that prior to 2002,
329 as recommended at the time, women took HRT as a routine treatment to relieve menopausal

330 symptoms and also to prevent complications secondary to oestrogen depletion, for example, reduced
331 bone mineral density. After 2002, we postulate that only women with severe VMS took HRT due to
332 perceived risks that led to an aversion of women, health professionals and clinical guidelines to
333 HRT.⁴⁶ It is surprising that earlier age of menopause was not associated with menopausal timing after
334 2002, as typically HRT will still be recommended until the average natural age of menopause for
335 women with an early age of menopause. The lack of association of age at menopause with HRT use
336 post 2002 highlights a potential under usage of HRT in the UK. Current UK National Institute for
337 Health and Care Excellence guidance is that HRT should be considered as a treatment for VMS⁴⁷ and
338 our analysis suggests that HRT may now be underutilised among such women. Our findings suggest
339 that genetic associations with HRT use that do not change over time are likely to be within the causal
340 pathway for VMS.

341 Our analyses were carried out in Europeans in UK Biobank, in which there are known biases towards
342 healthy and more affluent individuals⁴⁸, highlighting a need for replication in other cohorts and
343 ethnicities. The impact of changes to clinical practice regarding HRT use may not be the same in all
344 populations and future analyses must be mindful of other such gene by environment interactions.
345 Currently, linked primary care data in UK Biobank are limited to approximately half the cohort and the
346 coding of VMS depends on women consulting a GP with symptoms, and on these being recorded.
347 Inclusion of women with VMS without a GP record as controls in our analyses will have resulted in
348 reduced statistical power, but not false positives. The proxy phenotype of taking HRT did not
349 distinguish between types of medication and is based on retrospectively collected questionnaire data,
350 which may be subject to recall bias. However, another published study that analysed self-reported
351 medication data in UK Biobank identified the same genetic signal for HRT use.⁴⁹

352 By identifying genetic associations with VMS and with the proxy phenotype HRT use we replicated a
353 genetic signal for VMS in *TACR3* and identified a further two signals that require replication. We
354 identified significant gene-by-time interactions for HRT use associated with menopause timing but not
355 VMS, providing insights into the factors driving treatments and allowing refinement of a proxy
356 phenotype for VMS. Despite the strong evidence for a role of *TACR3* in VMS from clinical trials of
357 NK3R antagonist treatments, our study highlights limitations in current understanding that should be
358 addressed in future studies to further benefit the development of therapies for these common,
359 potentially life-changing symptoms.

360 **Data availability**

361 Genome-wide summary statistics will be made available at <https://www.ebi.ac.uk/gwas/>

362 **Author contributions**

363 AM and KSR designed the study. KSR led the data analysis with contributions from RNB, JML, JT,
364 GH and ARW. AM, KSR, RNB, JT, GH, ARW, MNW and TMF had access to the underlying UK
365 Biobank data. CJC provided data for the VMS meta-analysis. KSR, JKP, KAP, TMF, MNW and AM
366 reviewed and interpreted the results. KSR and AM wrote the first draft of the report. All authors
367 reviewed the drafts and contributed to the revision of the report.

368 **Declaration of interests**

369 We declare no competing interests.

370 **Acknowledgements**

371 This research was conducted using the UK Biobank resource under application number 871. KSR is
372 supported by Cancer Research UK [grant number C18281/A29019]. JKP is supported by the UKRI
373 Expanding Excellence in England award.

Table 1. Descriptive statistics for demographic and reproductive characteristics of women included as cases and controls in GWAS of VMS phenotypes.

	Vasomotor symptoms				Ever taken HRT			
	Cases		Controls		Cases		Controls	
	N	Mean (SD) / % (n)	N	Mean (SD) / % (n)	N	Mean (SD) / % (n)	N	Mean (SD) / % (n)
Age	14,261	56.08 (7.37)	77,767	60.55 (5.39)	72,622	61.82 (5.09)	80,686	59.6 (5.81)
Body mass index	14,209	27.25 (5.03)	77,489	27.31 (5.11)	72,371	27.04 (4.81)	80,417	27.00 (5.16)
Age at menarche	13,832	12.95 (1.6)	75,335	12.93 (1.57)	70,614	12.94 (1.57)	78,102	12.94 (1.54)
Age at natural menopause	4,956	50.17 (4)	42,920	50.47 (3.91)	33,250	49.53 (4.33)	72,629	50.7 (3.74)
Number of births	14,253	1.80 (1.15)	77,719	1.90 (1.16)	72,583	1.91 (1.14)	80,640	1.85 (1.18)
Number of pregnancies	13,977	2.31 (1.56)	76,437	2.34 (1.54)	71,437	2.39 (1.54)	79,382	2.29 (1.55)
Townsend deprivation index	14,241	-1.51 (2.9)	77,673	-1.57 (2.89)	72,544	-1.57 (2.91)	80,607	-1.62 (2.87)
Smoking status	14,087		76,901		71,709		79,915	
- never		56.2% (7,912)		58.6% (45,057)		53.1% (38,102)		61.8% (49,351)
- previous		33.8% (4,768)		34.1% (26,208)		38.8% (27,845)		31.3% (25,023)
- current		10.0% (1,407)		7.3% (5,636)		8.0% (5,762)		6.9% (5,541)
Vasomotor symptoms	14,261		77,767		33,015	16.8% (5,533)	36,106	7.5% (2,717)
Ever taken HRT	8,250	67.1% (5,533)	60,871	45.1% (27,482)	72,622		80,686	
Used HRT before 2002	6,779	59.9% (4,062)	55,748	40.1% (22,359)	57,740		80,686	
Used HRT after 2002	3,625	25.0% (908)	35,304	5.4% (1,915)	6,640		80,686	

Notes: All variables are at baseline except for age at menopause, which was calculated from the the most recent available visit. Ever taken HRT was defined in postmenopausal women and was identified by the answer to: "Have you ever used hormone replacement therapy (HRT)?". For categorical variables, N is the total number of cases or controls with information; Age at menarche excludes values <9 and >17 years; Age at natural menopause excludes values <40 and >60 years. Townsend deprivation scores range from negative values to positive values with smaller scores indicating less material deprivation.


Table 2. Genetic signals for VMS from primary GWAS analysis and secondary analyses of HRT proxy phenotypes.

Analysis	Variant id	Chr:pos (b37)	EA/OA (EAF)	Phenotype	Effect (95% CI) per allele	P	Gene
Primary discovery	rs34867104	chr4:104561892	AT/A (0.055)	VMS	OR=0.78 (0.74,0.82)	1.7×10^{-20}	TACR3 (0)
Meta-analyses**	rs112390256	chr4:104575473	A/G (0.055)	VMS	OR=0.76 (0.72,0.80)	3.7×10^{-27}	TACR3 (0)
Secondary discovery	rs34867104	chr4:104561892	AT/A (0.055)	Ever taken HRT	OR=0.85 (0.82,0.87)	1.1×10^{-26}	TACR3 (0)
Secondary discovery	rs146705358	chr4:104579107	AGGAATGTGCACAT/A (0.036)	Age ended HRT	-0.07 (-0.1,-0.05)	2.8×10^{-8}	TACR3 (0)
Secondary discovery	rs200480420	chr6:135016903	A/AT (0.999)	Time taken HRT	-0.51 (-0.69,-0.33)	4.3×10^{-8}	LINC01010 (+191.7kb)
Secondary discovery	rs7830431	chr8:10700317	G/A (0.597)	Age started HRT	0.03 (0.02,0.04)	2.9×10^{-8}	PINX1 (+2.9)

*Units for age started, ended and time taken HRT are standard deviations of the inverse rank transformed phenotype. **Variant rs112390256 represents the same genetic signal in TACR3 as that identified from the primary discovery analysis since it is in linkage disequilibrium with rs34867104 ($LD r^2=0.99$), which was not analysed in the earlier study

Chr=chromosome; CI=confidence interval; EA=effect allele; EAF=effect allele frequency; HRT=hormone replacement therapy; OA=other allele; OR=odds ratio; pos=position; VMS=vasomotor symptoms.

Figure 1. Genetic associations at the *TACR3* region: (A) Associations with VMS in UK Biobank. GWAS signals for age at menarche and the *TACR3* LOF allele (rs144292455 C>T) were not associated with VMS at $P < 5 \times 10^{-8}$ and show little correlation with the VMS signal ($LD r^2 < 0.2$); **(B) Associations with age at menarche in published GWAS.** GWAS signals for age at menarche and the *TACR3* LOF allele (rs144292455 C>T) were strongly associated with age at menarche. The VMS lead variant shows association at $P < 5 \times 10^{-8}$ with age at menarche in this univariate analysis though was not identified as an independent signal in published age at menarche GWAS. **(C) Univariate and conditional association analyses in UK Biobank.** The VMS lead variant was associated with age at menarche at $P < 5 \times 10^{-8}$ in univariate analyses (“Single”) but this association attenuated in analysis adjusting for the genotypes of the age at menarche GWAS signals (“Conditional”). The *TACR3* LOF allele (rs144292455 C>T) was strongly associated with later age at menarche but not VMS.




Notes: Variants shown are within +/-400kb of rs34867104, the lead variant for VMS, and $LD r^2$ shown is with rs34867104. Labelled variants are four variants associated with age at menarche within this region (triangles)¹⁴, VMS (purple diamond) and also the LOF variant rs144292455 (triangle). For clarity, other variants with $P = 1 \times 10^{-5}$ are not shown. Association statistics for rs144292455 were calculated in directly genotyped data in UK Biobank whereas all other statistics are from GWAS of imputed data. Association statistics for age at menarche GWAS are from published ReproGen meta-analyses excluding 23andMe¹⁴.


Figure 2. Effect of age at natural menopause on HRT use: (A) before 2002; and (B) after 2002.

Mendelian randomisation analyses showing effect of genetic instrument for age at menopause on odds of using HRT.

A.



B.



References

- 1 Politi MC, Schleinitz MD, Col NF. Revisiting the duration of vasomotor symptoms of menopause: A meta-analysis. *J. Gen. Intern. Med.* 2008. DOI:10.1007/s11606-008-0655-4.
- 2 Lobo RA. Hormone-replacement therapy: Current thinking. *Nat Rev Endocrinol* 2017; **13**: 220–31.
- 3 Rance NE, Dacks PA, Mittelman-Smith MA, Romanovsky AA, Krajewski-Hall SJ. Modulation of body temperature and LH secretion by hypothalamic KNDy (kisspeptin, neurokinin B and dynorphin) neurons: A novel hypothesis on the mechanism of hot flushes. *Front. Neuroendocrinol.* 2013; **34**: 211–27.
- 4 Krajewski-Hall SJ, Miranda Dos Santos F, McMullen NT, Blackmore EM, Rance NE. Glutamatergic Neurokinin 3 Receptor Neurons in the Median Preoptic Nucleus Modulate Heat-Defense Pathways in Female Mice. *Endocrinology* 2019; **160**: 803–16.
- 5 Prague JK, Roberts RE, Comninou AN, *et al.* Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial. *Lancet* 2017; **389**: 1809–20.
- 6 Fraser GL, Lederman S, Waldbaum A, *et al.* A phase 2b, randomized, placebo-controlled, double-blind, dose-ranging study of the neurokinin 3 receptor antagonist fezolinetant for vasomotor symptoms associated with menopause. *Menopause* 2020; **27**: 382–92.
- 7 Depypere H, Timmerman D, Donders G, *et al.* Treatment of Menopausal Vasomotor Symptoms with Fezolinetant, a Neurokinin 3 Receptor Antagonist: A Phase 2a Trial. *J Clin Endocrinol Metab* 2019; **104**: 5893–905.
- 8 Trower M, Anderson RA, Ballantyne E, Joffe H, Kerr M, Pawsey S. Effects of NT-814, a dual neurokinin 1 and 3 receptor antagonist, on vasomotor symptoms in postmenopausal women: a placebo-controlled, randomized trial. *Menopause* 2020; **27**: 498–505.
- 9 Prague JK. Neurokinin 3 receptor antagonists—prime time? *Climacteric* 2021; **24**: 25–31.
- 10 Navarro VM. Tachykinin signaling in the control of puberty onset. *Curr Opin Endocr Metab Res* 2020; **14**: 92–6.
- 11 Young J, Bouligand J, Francou B, *et al.* TAC3 and TACR3 defects cause hypothalamic congenital hypogonadotropic hypogonadism in humans. *J Clin Endocrinol Metab* 2010; **95**: 2287–95.
- 12 Topaloglu AK, Reimann F, Guclu M, *et al.* TAC3 and TACR3 mutations in familial hypogonadotropic hypogonadism reveal a key role for Neurokinin B in the central control of reproduction. *Nat Genet* 2009; **41**: 354–8.
- 13 Lunetta KL, Day FR, Sulem P, *et al.* Rare coding variants and X-linked loci associated with

- age at menarche. *Nat Commun* 2015; **6**: 7756.
- 14 Day FR, Thompson DJ, Helgason H, *et al.* Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. *Nat Genet* 2017; **49**: 834–41.
 - 15 Crandall CJ, Manson JE, Hohensee C, *et al.* Association of genetic variation in the tachykinin receptor 3 locus with hot flashes and night sweats in the women’s health initiative study. *Menopause* 2017; **24**: 252–61.
 - 16 Bycroft C, Freeman C, Petkova D, *et al.* Genome-wide genetic data on ~500,000 UK Biobank participants. *bioRxiv* 2017. DOI:<http://dx.doi.org/10.1101/166298>.
 - 17 Allen N, Sudlow C, Downey P, *et al.* UK Biobank: Current status and what it means for epidemiology. *Heal Policy Technol* 2012; **1**: 123–6.
 - 18 Writing Group for the Womens Health Initiative. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women. *JAMA* 2002; **288**: 321–33.
 - 19 Frayling TM, Beaumont RN, Jones SE, *et al.* A Common Allele in FGF21 Associated with Sugar Intake Is Associated with Body Shape, Lower Total Body-Fat Percentage, and Higher Blood Pressure. *Cell Rep* 2018; **23**: 327–36.
 - 20 Loh PR, Tucker G, Bulik-Sullivan BK, *et al.* Efficient Bayesian mixed-model analysis increases association power in large cohorts. *Nat Genet* 2015. DOI:10.1038/ng.3190.
 - 21 Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* 2010; **26**: 2190–1.
 - 22 Day FR, Ruth KS, Thompson DJ, *et al.* Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. *Nat Genet* 2015; **47**: 1294–303.
 - 23 Chang CC, Chow CC, Tellier LCAM, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: Rising to the challenge of larger and richer datasets. *Gigascience* 2015; **4**. DOI:10.1186/s13742-015-0047-8.
 - 24 McLaren W, Gil L, Hunt SE, *et al.* The Ensembl Variant Effect Predictor. *Genome Biol* 2016; **17**: 1–14.
 - 25 Yates AD, Achuthan P, Akanni W, *et al.* Ensembl 2020. *Nucleic Acids Res* 2020. DOI:10.1093/nar/gkz966.
 - 26 Ward LD, Kellis M. HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids Res* 2012; **40**: D930-4.
 - 27 Wang D, Liu S, Warrell J, *et al.* Comprehensive functional genomic resource and integrative

- model for the human brain. *Science* (80-) 2018; **362**. DOI:10.1126/science.aat8464.
- 28 Nellore A, Jaffe AE, Fortin JP, *et al.* Human splicing diversity and the extent of unannotated splice junctions across human RNA-seq samples on the Sequence Read Archive. *Genome Biol* 2016; **17**: 1–14.
- 29 Turner SD. qqman: an R package for visualizing GWAS results using Q-Q and manhattan plots. *J Open Source Softw* 2018; **3**: 731.
- 30 Pruim RJ, Welch RP, Sanna S, *et al.* LocusZoom: regional visualization of genome-wide association scan results. *Bioinformatics* 2011; **26**: 2336–7.
- 31 Szustakowski JD, Balasubramanian S, Kvikstad E, *et al.* Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank. *Nat Genet* 2021; **53**: 942–8.
- 32 Zhou W, Zhao Z, Nielsen JB, *et al.* Scalable generalized linear mixed model for region-based association tests in large biobanks and cohorts. *Nat Genet* 2020; **52**: 634–9.
- 33 Mbatchou J, Barnard L, Backman J, *et al.* Computationally efficient whole-genome regression for quantitative and binary traits. *Nat Genet* 2021; **53**: 1097–103.
- 34 Gianetti E, Tusset C, Noel SD, *et al.* TAC3/TACR3 Mutations Reveal Preferential Activation of Gonadotropin-Releasing Hormone Release by Neurokinin B in Neonatal Life Followed by Reversal in Adulthood. *J Clin Endocrinol Metab* 2010; **95**: 2857–67.
- 35 Wright CF, West B, Tuke M, *et al.* Assessing the Pathogenicity, Penetrance, and Expressivity of Putative Disease-Causing Variants in a Population Setting. *Am J Hum Genet* 2019; **104**: 275–86.
- 36 Tyrrell J, Mulugeta A, Wood AR, *et al.* Using genetics to understand the causal influence of higher BMI on depression. *Int J Epidemiol* 2018. DOI:10.1093/ije/dyy223.
- 37 Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. *Genet Epidemiol* 2016; **40**: 304–14.
- 38 Bowden J, Smith GD, Burgess S, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression. *Int J Epidemiol* 2015; **44**: 512–25.
- 39 Prague JK, Roberts RE, Comninou AN, *et al.* Neurokinin 3 receptor antagonism rapidly improves vasomotor symptoms with sustained duration of action. *Menopause* 2018; **25**: 862–9.
- 40 Jayasena CN, Comninou AN, Stefanopoulou E, *et al.* Neurokinin B administration induces hot flushes in women. *Sci Rep* 2015; **5**: 1–7.

- 41 Ruth KS, Day FR, Hussain J, *et al.* Genetic insights into biological mechanisms governing human ovarian ageing. *Nature* 2021; **596**: 393–7.
- 42 Rance NE. Menopause and the human hypothalamus: Evidence for the role of kisspeptin/neurokinin B neurons in the regulation of estrogen negative feedback. *Peptides* 2009; **30**: 111–22.
- 43 Francou B, Bouligand J, Voican A, *et al.* Normosmic Congenital Hypogonadotropic Hypogonadism Due to TAC3/TACR3 Mutations: Characterization of Neuroendocrine Phenotypes and Novel Mutations. *PLoS One* 2011; **6**: e25614.
- 44 Ruth KS, Day FR, Tyrrell J, *et al.* Using human genetics to understand the disease impacts of testosterone in men and women. *Nat Med* 2020; **26**: 252–8.
- 45 Malherbe P, Knoflach F, Marcuz A, *et al.* Mapping the binding pocket of a novel, high-affinity, slow dissociating tachykinin NK3 receptor antagonist: Biochemical and electrophysiological characterization. *Neuropharmacology* 2014; **86**: 259–72.
- 46 Crawford SL, Crandall CJ, Derby CA, *et al.* Menopausal Hormone Therapy Trends Before Versus After 2002: Impact of the Women’s Health Initiative Study Results. *Menopause* 2018; **26**: 588–97.
- 47 National Institute for Health and Care Excellence. Menopause: Diagnosis and Management. 2015.
- 48 Fry A, Littlejohns TJ, Sudlow C, *et al.* Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants with the General Population. *Am J Epidemiol* 2017. DOI:10.1093/aje/kwx246.
- 49 Meijssen JJ, Shen H, Vemuri M, Rasgon NL, Koenen KC, Duncan LE. Shared genetic influences on depression and menopause symptoms. *Psychol Med* 2021; : 1–11.